American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
April 6, 2021
Earnings Call Speaker Segments
Stephanie Prince
executiveThanks, Elissa, and I appreciate all of you being with us today. Prior to handing the call to management, I want to offer these comments about forward-looking statements. Kindly be aware that a range of things we might say during this conference call regarding anticipated future expectations, plans and prospects for the company are forward-looking statements, as defined by safe harbor provisions included in the Private Securities Litigation Reform Act of 1995. Results that actually occur could differ materially from what such forward-looking statements suggest, owing to a number of significant factors, such as the ones addressed in the company's SEC filings. Those include the annual report on Form 10-K covering the year that closed on December 31, 2020, the Form 10-Q for the periods that concluded on March 31, June 30 and September 30, 2020, along with the definitive proxy statement for the Annual Meeting of Shareholders that took place on June 26, 2020; we The company takes on no duty to refresh the information within this conference call. At this point I'd like to pass the call to Ray Stachowiak, AMS's CEO. Ray?
Ray Stachowiak
executiveThanks, Stephanie. Hello, everybody, and good afternoon. We appreciate you being with us for the conference call covering our 2020 fourth quarter and year-end earnings. I'll start things off with a few comments; after that, Craig Tagawa, who serves as our President, COO and CFO, will walk through results for the business and operations; Alexis Wallace, our Chief Accounting Officer, will follow with a review of the financials. Once that's done, Craig, Alexis, Ernie Bates — our Senior VP, Sales and Business Development and International Operations — and I will take your questions. Earlier today, we shared news of a significant step that has made this a stronger company and should boost long-term shareholder value as we strive to build a more solid foundation for achieving our aim of greater growth and lasting profitability. That step involves writing down impaired assets on our balance sheet totaling $8.3 million, which is largely a noncash charge. This asset write-down should leave us with a substantially stronger balance sheet, and Craig will go into more detail on that shortly. The decisive move forms part of our strategic plan, which also covers diversifying what we offer, expanding geographically and providing additional kinds of financing solutions so the company's revenue streams grow. To be more specific, our offerings now go beyond proton beams and gamma Knives to encompass MR-guided LINAC and more advanced linear accelerators. Beyond that, we keep seeking further chances to grow geographically, such as our purchase of the sole Gamma Knife center located in the nation of Ecuador, which closed this past June. As we pursue growth in our revenue streams, we're building more flexibility into both our wholesale and retail financing solutions. Taken together, I'm confident these moves place us on the right path toward our aim of lasting profitability. Plenty of opportunities for future growth lie ahead, and we can deliver enormous flexibility to the marketplace and to our clients through the many different ways we can serve their needs. The team and I are eager to build on this strong base. At this point, I'll hand the call to Craig for the operational review of the fourth quarter.
Craig Tagawa
executiveRay, thank you — and hello, everyone, this afternoon. Our Q4 volumes took a hit from surges of COVID-19, while routine-care hospital visits were something patients held back on as well. On top of that came the normal dip that accompanies the holidays, and together these factors yielded a 3.7% drop in total revenue compared with Q4 of 2019. The better average reimbursement we receive at our proton beam radiation therapy center, plus the contribution from our June purchase of Gamma Knife Center Ecuador, masked the pandemic-driven volume losses year over year across both the PBRT and Gamma Knife businesses. For Gamma Knife, revenue was basically level with the fourth quarter of 2019 — a result caused by reduced volumes at existing centers, which was then offset by the addition of GKCE. On the company's proton therapy system, revenue was down 5.6% compared with the fourth quarter of 2019. Higher average reimbursement in the quarter helped make up for lower volume. Gamma Knife procedures increased 3.1% relative to the same period a year earlier. These results show a favorable impact from buying GKCE, since Gamma Knife volumes at centers already up and running were 7.8% below what those same centers recorded a year ago. Proton therapy fractions overall were 25% lower than in the fourth quarter of 2019. That year-over-year decline came in part because of a COVID-19 surge during the fourth quarter, made worse by downtime tied to maintenance. In the fourth quarter, gross margin came in at 22.3% of revenue, versus 30.1% in the same period of 2019. The decline stemmed from reduced revenue combined with a 7.1% rise in cost of revenue compared with the prior period, reflecting our heavy fixed cost structure, which doesn't fall in tandem with shrinking volumes. For Q4 2020, we posted a net loss of $6,231,000, whereas Q4 2019 brought net income of $193,000. Included in that fourth-quarter loss is a pretax write-down of impaired assets amounting to $8,264,000. Within that impaired group are six Gamma Knife machines whose client agreements won't be extended, along with the expenses tied to taking them out, as well as two deposits made toward buying proton beam systems, the interest that had been capitalized on those, and additional charges. The PBRT deposits, in our judgment, have suffered an impairment that isn't temporary. That's because of how COVID-19 has affected medical centers and their ability right now to take on major capital projects aimed at a selective patient population, plus how long it would realistically take to work out and put in place a proton therapy initiative. Even so, our view hasn't changed that proton therapy will matter greatly as part of the radiation therapy offerings at a cancer center. Of those 6 Gamma Knife units, we impaired 2 that had been pulled from service in earlier years, 1 that came out of service during 2020, and 3 that either already have been or are expected to be taken out of service in 2021. Within the impairment write-off, there's $1,350,000 that represents our estimate of the cost to de-install and remove 4 Gamma Knife units. That portion of the write-down is cash. The remaining $6,914,000 is a noncash charge. It's not typical for us to see this many agreements lapse without being renewed so close together. Roughly 18 months was the span over which 5 agreements were scheduled to expire. The majority were long-term customers who had already renewed at least once; yet when weighing whether to lease or buy, plenty of them had enough cash available to bring the equipment in-house. When a center chooses to go in-house, it actually speaks well of how we have built a successful Gamma Knife program. After adding back the impairment charge, adjusted EBITDA came to $2,538,000 for the fourth quarter, versus $2,056,000 in the fourth quarter of 2019. We closed the quarter with a solid cash position of $4.3 million. 2 Cobalt-60 reloads were completed by us during the first quarter of 2021. There's another upgrade in our pipeline that hasn't been completed yet — it's for Gamma Knife Center Ecuador and is scheduled to be installed halfway through the year. Once it's in place, it will be one of only a handful of gamma knives in all of South America. As Ray mentioned, we're still in discussions with potential customers about the broader range of products we now offer. Looking ahead, we'll continue monitoring COVID-19 infection numbers carefully in case they create any further disruption to how we operate; during this first quarter, certain sites of ours are still experiencing the pandemic's ongoing effects. At some point in 2025, we do anticipate that COVID-19's impact will diminish, although it's hard to say exactly when that will happen; once it does, we think we'll begin getting back to the volumes we've seen historically and make up a portion of the demand that has been held back. As we mentioned before, we expect selling and administrative expenses to have a lower fixed rate in 2021. I'll now pass things over to Alexis, who will walk through the financials in more detail. Alexis?
Alexis Wallace
executiveI appreciate that, Craig, and good afternoon to all of you. Prior to starting my prepared comments, I want to direct your attention toward the fourth quarter and year-end earnings press release we put out earlier today. Should you require a copy, you can find it on our website, ashs.com, listed under press releases within the Investors tab. Now, moving on to our fourth quarter results. During the 3 months that concluded on December 31, 2020, total revenue came in at $4,608,000, which represents a decline of 3.7% from the $4,786,000 we reported for the fourth quarter of 2019. Revenue in the fourth quarter from the company's proton therapy system installed at Orlando Health in Florida reached $1,403,000, down 5.6% relative to the fourth quarter of 2019. Total proton therapy fractions fell 25% versus the fourth quarter of 2019. The company's Gamma Knife operations generated revenue of $3,205,000, which was a 0.8% decline from the fourth quarter of 2019. Gamma Knife procedures rose by 3.1%, reaching 427 in the fourth quarter of 2020, up from 414 during the same period. Gross margin for the fourth quarter of 2020 dropped to $1,027,000, or 22.3% of revenue, versus a gross margin of $1,441,000, or 30.1% of revenue, in the fourth quarter of 2019. Selling and administrative costs grew by 22.5%, hitting $1,052,000 in the fourth quarter, compared with $859,000 in the fourth quarter of 2019. This period-over-period rise stems from higher tax and audit expense, stock-based compensation, and software-related expenses. Operating loss for the fourth quarter of 2020 stood at $8,543,000, versus operating income of $279,000 in the fourth quarter of 2019. When excluding the pretax write-down of impaired assets during the quarter, which totaled $8,264,000, the operating loss came to $279,000. Net loss for the fourth quarter of 2020 was $6,231,000, or 1.01 per share, which includes the pretax write-down of impaired assets of $8,264,000. That compares with net income of $193,000, or $0.03 per diluted share, for the fourth quarter of 2019. Adjusted EBITDA, a non-GAAP financial measure, came in at $2,538,000 for the fourth quarter of 2020, versus $2,056,000 for the fourth quarter of 2019; now turning to the annual results. For the full year of 2020, which ended December 31, revenue declined 13.4%, landing at $17,837,000, compared with revenue of $20,605,000 for the 12 months of 2019. The company recorded no revenue from IGRT equipment during the 12-month 2020 period, versus $840,000 in the comparable period of 2019, following the expiration of the company's contracts and the equipment is fully depreciated and sold. Proton therapy revenue declined 0.8%, coming to $6,167,000 for the 12 months of 2020. Total proton therapy fractions for 2020 were 5,868, a decline of 2.5%. Gamma Knife revenue dropped 13.9% to $11,670,000 for the 12 months of 2020. The number of gamma knife procedures during the 12 months of 2020 was 1,530, an increase of 2.1%. Operating loss for 2020 was $9,463,000, compared with operating income of $1,542,000 for 2019. If we set aside the pretax write-down tied to impaired assets from Q4 2020, which came to $8,264,000, then our operating loss for 2020 stood at $1,199,000. For the full 12 months of 2020, the net loss reached $7,058,000, equal to $1.14 per share, and that figure includes the $8,264,000 pretax write-down on impaired assets. Compare that with net income of $659,000, or $0.11 per diluted share, for the 12 months of 2019. Adjusted EBITDA came in at $7,776,000 for 2020, versus $9,676,000 for 2019. As of December 31, 2020, shareholders' equity was $23,650,000, or $4.08 per outstanding share. That stacks up against shareholders' equity of $31,811,000, or $5.47 per outstanding share, as of December 31, 2019; that wraps up the formal portion of what we have to present. Elissa, we'd like to hand the call back to you so you can take questions.
Tony Kamin
analystSo, I suppose the first thing I want to ask — maybe this goes to Ray or to Craig — regarding that Mevion write-down on the deposits: is this a technical write-down? What I mean is, if down the road you manage to line up buyers for a couple of those Mevion units, does that discount go away for you? And I bring that up because I saw that Mevion sold a system, and it appears it was only a couple of weeks back, to a location in North Carolina. So I'm somewhat — I'd just like a bit more clarity on what this actually amounts to.
Ray Stachowiak
executiveYeah. Tony, good question. We took that off our books using the information available to us. Even so, we continue to view that deposit as sitting in our account with Mevion; we remain bullish on proton beam systems, and specifically on Mevion proton beam systems. So this is purely an accounting matter, I'd say, and not about our relationship with Mevion.
Tony Kamin
analystCertainly; that helps a lot. Then my follow-up concerns the — you brought up MR/LINAC's fresh equipment categories that AMS is going to be shifted into. Could you elaborate a bit further on that, specifically which other kinds of machines, if you're able to share that at this point? And do you believe this could begin demonstrating some progress during this calendar year in terms of, clearly, no guarantees, but is it your view that sales efforts are under — are in motion, and we might begin to see a few of these new products start contributing to the portfolio?
Ray Stachowiak
executiveThat's a really good question, I think. There are a few distinct components to it. I'll likely turn to Craig for the product offerings and the various types of products. But prior to that, I'd like to just bring up the idea of a stronger balance sheet that we have. And our balance sheet is stronger since we are no longer economically committed to elective gamma knives and/or Mevion proton beam systems; we love those products, we love working with those vendors, and we'll continue to work with those vendors and those products; they got great products, we support them; we continue to believe in those products and those vendors. But we're no longer economically committed to only those products; so having said that, I will point over to Craig, and Craig maybe you can expand on the different types of product offerings?
Craig Tagawa
executiveRight. What we're examining are genuinely sophisticated linear accelerators — machines that integrate MRI capabilities, which gives you a clearer view of soft tissue. Those items fall somewhere between $6 million and $10 million, roughly. That makes it an attractive path for us, since plenty of hospitals will want someone to partner with them on bringing in this newer technology. It resembles the situation when the Gamma Knife first came onto the scene — hospitals were seeking partners, organizations like American Shared, willing to take on a portion of the risk, whether that risk involved the technology itself, the reimbursement side, or the patient volumes. So we regard this as a highly promising direction for us to move into. Regarding one point you raised, Tony, about whether revenues would show up immediately — the response is that during 2021 you largely would not see them, because installation of these systems requires a fair amount of time. Even so, we view the technology as quite promising; we're likewise examining other technologies involving PET/CT, even though the FDA hasn't cleared that one as of yet. We're watching it carefully, and Ernie has devoted a great deal of attention to assessing what opportunity that market might hold. Once more, that's an advanced linear accelerator that, in our view, has a capital cost structure well suited for a company such as American Shared to join with hospitals on; we're additionally reviewing more conventional linear accelerators, where hospitals might be interested in partnering with us under a revenue-sharing arrangement in order to bring in additional IGRT machines. So we're evaluating every one of those categories of linear accelerators, alongside our gamma knives, our other stereotactic radiosurgery devices, and our proton therapy devices.
Tony Kamin
analystAll right. And one last thing I wanted to ask. Could you share your thoughts on what comes after — ideally quite soon — the post-COVID stretch for hospitals, and what you're picking up regarding their views on proceeding with new equipment purchases? The reason I'm asking is that I've spoken with a few folks at hospitals, and it sounds like this has been an extremely difficult year for them money-wise, yet at the same time they're eager to begin looking at ways to grow that don't require heavy upfront capital outlays. So it seems like perhaps an ideal — possibly the strongest setup in quite some time for a business like AMS — but what are you picking up? And how do you view the climate for hospital spending?
Ray Stachowiak
executiveThere are, I'd say, a few patterns we're noticing, and in a sense they cancel one another out. First, procedure volumes still bear the mark of the pandemic. They haven't returned to where they were before the pandemic; and because of that, hospitals have, I'd put it, held off until their finances are sorted out and/or conditions get back to pre-pandemic norms. Conversely, certain hospitals have come through this pandemic in solid shape; and in the current market, they can obtain funds without difficulty. And, in some instances, they lean toward dealing straight with vendors in order to grow their operations, given the simple access to capital they might enjoy. So it really differs. But those represent two roughly counterbalancing patterns we're seeing, and our task is simply to zero in and concentrate on the ones that suit us better.
Ed Corcoran
analystThe write-down interests me a lot, naturally, since return on capital was always — and book value was always seen as a cause of the shares' underperformance. But when it comes to the assets themselves: those units you're writing down, are they sitting in storage? Or are you attempting to resell them on the aftermarket? And a further question: have appraisals been done on this equipment, so that it truly is 0, or is this purely an accounting write-down? Those are the handful of questions I have about those assets.
Ray Stachowiak
executiveEd, appreciate you being with us today. I believe we're in a setting where an extraordinary quantity of contracts were expiring inside a brief window, roughly 5 contracts across about an 18-month span, and that's quite abnormal. With 15 domestic gamma knives and 10-year contract terms, you'd expect only 1 or 2 to lapse annually. We had an excessive number of contracts that did lapse, and they wished to end their agreements as well. So we view it as an anomaly, those factors converging nearly simultaneously; and whether we can recover that value hinges on that supply and demand. No readily available marketplace exists for elective gamma knives. Plus de-installing them and reinstalling them elsewhere is extremely costly; so we've managed to recover value through extending, renewing our agreements, upgrading the equipment — and most of those upgrades are software-type upgrades — and we've succeeded at doing that.
Ed Corcoran
analystGot it. That was a really clear explanation. What I'm asking is, when these units come out of service — since you have several at once, so the market probably won't absorb them, or at least not the U.S. market — are they then sold off to an equipment broker? Do they end up sitting in a warehouse? What interests me more is the physical side of things. And then the other thing: was an appraisal done on these?
Ray Stachowiak
executiveCraig, do you want to weigh in on that?
Craig Tagawa
executiveOkay. Of those units, 2 out of the 6 were quite old — earlier versions of the units that truly had no — we couldn't determine any remaining value in them, Ed. So we recorded those as a write-down. Another 2, once we de-installed them, we basically folded those into the de-install portions of our Elekta agreement; therefore those 2 are no longer there. There are a couple more where we haven't yet figured out the arrangement precisely. So I'd say those 2 are still available; but from a finance perspective...
Ed Corcoran
analystSo that means — wait, so that means — Craig, may I jump in and ask, does that mean they'll be dismantled for parts, or — what exactly does that mean? I've had a lot of equipment over the years, and I'm trying to figure out what happens to those assets afterward. And I really do appreciate — you folks have provided plenty of details over the 10 years I've held the stock; we never received this information before, so I commend you for having this discussion, because previously you withheld it for supposedly competitive reason. So this is — I appreciate it. And I just wanted to — I want to understand my investment and what became of that book value? Is it — and you're laying it out in a very detailed manner. So I'll just go to that last bit of detail. Where do these assets sit, or are they scrapped? And will you put — hand them to a broker to try to sell them in a market that will accept those at a low-cost basis and try to use them with patients?
Craig Tagawa
executiveAs Ray mentioned, these are very — relocating them is very expensive; we haven't decided how we will dispose of these, the last 2. And so those are still undecided, Ed, so I can't give you any specificity as to how those will end up. But from an accounting standpoint, we think they were impaired, and we did take the write-down on those is what I would say.
Ray Stachowiak
executiveAlright Ed, in a number of these cases, once that equipment gets taken out physically, it goes back to the vendor. And to offset things, we aim to lower what it costs us to pull the gear out through that idea of returning the actual hardware.
Ed Corcoran
analystAll right, that's logical. It stands to reason since they're the top source for personnel — perhaps the spare parts hold some worth, or maybe there's value we, as an operator or financier, could never capitalize on. That's the reason I inquired whether they approach a broker, the equipment manufacturer, or a party that re-leases it. So that's understood, and I — assuming no market exists, then there's no market once you factor in relocation costs; that's a significant point that wasn't very apparent — if moving runs into millions of dollars, it likely does. And it's preferable not to concentrate on that and instead concentrate on new equipment.
Ray Stachowiak
executiveUnderstood; that's a fine question, Ed. I appreciate you asking.
Ed Corcoran
analystSo, given that you think the valuation is 0, an appraisal isn't necessary? Or is it just that there might be some kind of decrease down the road when buying equipment or services from that vendor?
Ray Stachowiak
executiveOr a lower expense for taking the equipment out.
Ed Corcoran
analystAll right. All right. That's reasonable. Yeah. Precisely. All right. So you're not including — we're not setting aside any closure or post-closure funds across the lifespan of the — these — this machinery. Right?
Ray Stachowiak
executiveMy expectation isn't that this machinery will be removed during the first 10-year stretch, at minimum. One of the accounts that lapsed had been with us since 1999. So generally, that isn't necessary given the long-term relationships we establish.
Ed Corcoran
analystAll right. I'm merely putting forward that, supposing you have — supposing a contract running 10 years exists and there's a chance of $0.5 million for scrapping or relocating, it might be worthwhile for us to build modest accruals gradually, since this situation does exist. That's an actual expense that can be recorded. In sectors where I've worked, we've had closure and post closure costs that we accrue for — precisely for this, though — that's a separate sector, yet broadly speaking, the — where equipment, fixed plant and property exist, we could do that at any time, and that sits in installation for taxes since it's an actual expense that can be recorded. And afterward it will come out of earnings, but it will produce an EBITDA that's, naturally, not taxable, as you get a tax write-off on that closure and post-closure cost; so I could discuss that with you privately, just in general terms. I have no further questions, but I truly appreciate your time and what you folks are attempting as a team here regarding managing costs and simply trying to bring about a new chapter for the company. Thank you.
Ray Stachowiak
executiveThanks, Ed.
Ray Stachowiak
executiveWe appreciate everyone being here today. There's a lot of enthusiasm on our side regarding what lies ahead for AMS. Should anything else come to mind before our Q1 call takes place in the middle of May, feel free to reach out to us straight away. Take care of yourselves, enjoy the rest of your day, keep watching for updates, and farewell.
Operator
operatorThat brings us to the end of this call. We appreciate your joining us for today's presentation. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.